Concepedia

Andy Blake-Haskins

AB

Statistics

Publications

7

Citations

491

H-Index

7

Active since

2014

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Moffitt Cancer Center

Gabrail Cancer Center

Sidney Kimmel Comprehensive Cancer Center

Angeles Clinic and Research Institute

Andy Blake-Haskins is an author at Memorial Sloan Kettering Cancer Center specializing in immune checkpoint inhibitors, oncology, and pd-l1 blockade.

Publications per year

2014–2022

7

Publications

7

Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.

Neil H. Segal, Scott Antonia, Julie R. Brahmer et al. · Journal of Clinical Oncology · 2014 · 172 citations

, , +17

A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.

Jose Lutzky, Scott Antonia, Andy Blake-Haskins et al. · Journal of Clinical Oncology · 2014 · 104 citations

, , +17

Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.

Julie R. Brahmer, Naiyer A. Rizvi, Jose Lutzky et al. · Journal of Clinical Oncology · 2014 · 78 citations

, , +17

A Phase I Multi-Arm Dose-Expansion Study of the Anti-Programmed Cell Death-Ligand-1 (Pd-L1) Antibody Medi4736: Preliminary Data

Neil H. Segal, Omid Hamid, W. Hwu et al. · Annals of Oncology · 2014 · 55 citations · Full text

, , +16

Clinical Activity and Safety of Medi4736, an Anti-Pd-L1 Antibody, in Patients with Head and Neck Cancer

Matthew G. Fury, Sai‐Hong Ignatius Ou, Ani Sarkis Balmanoukian et al. · Annals of Oncology · 2014 · 30 citations · Full text

, , +14

1–5 of 7